Internal Medicine, Rheumatology · Albuquerque, NM
NPI
1356435747
Since 2006
Specialty
Internal Medicine, Rheumatology
Code 207RR0500X
Group practices
1
Medicare group memberships
Hospitals
0
Hospital affiliations
8200 Louisiana Blvd NE, New Mexico Rheumatology LLC
Albuquerque, NM, 87113
Phone (505) 828-2400
Groups this clinician bills Medicare through
Medicare paid, 2024
$1.1M
51,140 services
Medicare patients, 2024
110
Average age 73
Drug cost, 2024
$507K
804 prescriptions
Company payments, 2025
$345
From 2 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Peter Rosandich was code J0129 (injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered)), 9,000 times for 12 patients. In total Peter Rosandich billed 51,140 services in 35 codes, and Medicare paid $1.1M.
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2010-12-02.
| Code | Setting | Services | Patients | Paid per service | Medicare paid |
|---|
| J0129 Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | Office | 9,000 | 12 | $33.78 | $304K |
| J0897 Injection, denosumab, 1 mg | Office | 3,000 | 29 | $20.45 | $61K |
| J2919 Injection, methylprednisolone sodium succinate, 5 mg | Office | 946 | 17 | $0.22 | $205 |
| 96413 Chemotherapy Administration | Office | 290 | 49 | $89.93 | $26K |
| 99214 Office E&M - Established | Office | 164 | 85 | $89.00 | $15K |
| 96415 Chemotherapy Administration | Office | 120 | 22 | $19.87 | $2,385 |
| 96401 Chemotherapy Administration | Office | 72 | 30 | $47.25 | $3,402 |
| 36415 Venipuncture Blood Collection | Office | 51 | 25 | $8.65 | $441 |
| 96374 Injection Administration | Office | 50 | 17 | $25.51 | $1,275 |
| 96375 Injection Administration | Office | 40 | 16 | $10.72 | $429 |
| J1200 Injection, diphenhydramine hcl, up to 50 mg | Office | 39 | 15 | $0.64 | $25.12 |
| 20610 Joint Injection | Office | 23 | 13 | $53.31 | $1,226 |
| 99215 Office E&M - Established | Office | 22 | 17 | $129.49 | $2,849 |
By year: 2022 $933K for 45,176 services; 2023 $1.3M for 54,824 services; 2024 $1.1M for 51,140 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 36415 Venipuncture Blood Collection | 51 | 25 | $8.65 | $441 |
Medicare prescription drug claims, 2024
In 2024, the drug Peter Rosandich prescribed most often to Medicare patients was Methotrexate (Methotrexate Sodium), with 314 prescriptions and refills. In total Peter Rosandich wrote 804 Medicare prescriptions that cost $507K.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Methotrexate Methotrexate Sodium | 314 | 682 | 68 | $8,859 |
| Prednisone Generic | 71 | 130 | 19 | $742 |
| Hydroxychloroquine Sulfate Generic | 68 | 153 | 19 | $1,633 |
| Leflunomide Generic | 65 | 173 | 18 | $4,270 |
| Amjevita(Cf) Autoinjector Adalimumab-Atto | 36 | 36 | Under 11 | $108K |
| Allopurinol Generic | 34 | 68 | Under 11 | $275 |
| Azathioprine Generic | 33 | 85 | Under 11 | $1,776 |
| Enbrel Sureclick Etanercept | 16 | 16 | Under 11 | $112K |
| Celecoxib Generic | 14 | 32 | Under 11 | $262 |
| Actemra Tocilizumab | 13 | 13 | Under 11 | $32K |
| Folic Acid Generic | 13 | 23 | Under 11 | $111 |
| Amjevita(Cf) Adalimumab-Atto | 11 | 11 | Under 11 | $70K |
Brand drugs: - claims; generic drugs: 668 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Peter Rosandich $345 ($345 in general payments such as food, travel and fees) from 2 companies. The largest payer was Amgen Inc. with $330.
| Company | Payments | Amount |
|---|---|---|
| Amgen Inc. AMGN | 22 | $330 |
| Lundbeck LLC | 1 | $14.37 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.